Minerva Neurosciences | NERV - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Adma Biologics USD 80.75M 8.07M 2026-03
ALKERMES USD 331.33M 7M 2026-03
AstraZeneca USD 12.86B 251M 2026-06
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Cipla INR 44.1B 5B 2026-06
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 352K 63.44M 2026-03
CSL USD 4.46B 2.71B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
GlaxoSmithKline GBP 6.51B 757M 2026-06
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Ionis Pharmaceuticals USD 265M 22M 2026-06
J&J USD 18.55B 1.31B 2026-06
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 8.71B 602M 2026-06
Takeda JPY 813.22B 124.39B 2026-06
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12